Immunology of VIP: A review and therapeutical perspectives

被引：164

作者：

Gomariz, RP ^{[1
]}

Martinez, C ^{[1
]}

Abad, C ^{[1
]}

Leceta, J ^{[1
]}

Delgado, M ^{[1
]}

机构：

[1] Univ Complutense Madrid, Fac Biol, Dept Biol Celular, E-28040 Madrid, Spain

来源：

CURRENT PHARMACEUTICAL DESIGN | 2001年 / 7卷 / 02期

关键词：

D O I：

10.2174/1381612013398374

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Vasoactive intestinal peptide (VIP) is a neuropeptide with a broad distribution in the body that exerts very important pleiotropic functions in several systems. The present work reviews the immunology of VIP. Being daring, this neuropeptide could be included in the group of cytokines since it is produced and secreted by different immunocompetent cells in response to various immune signals, plays a broad spectrum of immunological functions, and exerts them, in a paracrine and/orautocrine way, through three different specific receptors. Although VIP has been classically considered as an immunodepressant agent, and its main described role has been as an anti-inflammatory factor, several evidences suggest that a better way to see this peptide is as a modulator of the homeostasis of the immune system. In the last decade, the pharmacology of VIP has spectacularly grown, and VIP itself, as well as more stable VIP-derived agents, have been used or proposed as efficient therapeutical treatments of several disorders, specially inflammatory and autoimmune diseases, such as septic shock, rheumatoid arthritis, multiple sclerosis, Crohn's disease and autoimmune diabetes. A broad field of perspectives is actually open, and further investigations will help us to definitively understand the immunology of this "very important peptide".

引用

页码：89 / 111

页数：23

共 212 条

[71] Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: Neuroprotective drug design [J].

Gozes, I ;

Perl, O ;

Giladi, E ;

Davidson, A ;

Ashur-Fabian, O ;

Rubinraut, S ;

Fridkin, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :4143-4148

[72] Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide [J].

Gozes, I ;

Bardea, A ;

Reshef, A ;

Zamostiano, R ;

Zhukovsky, S ;

Rubinraut, S ;

Fridkin, M ;

Brenneman, DE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (01) :427-432

[73] Neuropeptides and neuronal survival: Neuroprotective strategy for Alzheimer's disease [J].

Gozes, I ;

Bardea, A ;

Bechar, M ;

Pearl, O ;

Reshef, A ;

Zamostiano, R ;

Davidson, A ;

Rubinraut, S ;

Giladi, E ;

Fridkin, M ;

Brenneman, DE .

NEUROPEPTIDES IN DEVELOPMENT AND AGING, 1997, 814 :161-166

[74] A VIP ANTAGONIST DISTINGUISHES VIP RECEPTORS ON SPINAL-CORD CELLS AND LYMPHOCYTES [J].

GOZES, Y ;

BRENNEMAN, DE ;

FRIDKIN, M ;

ASOFSKY, R ;

GOZES, I .

BRAIN RESEARCH, 1991, 540 (1-2) :319-321

[75]

Graf AH, 1998, ANTICANCER RES, V18, P2041

[76] NEUROENDOCRINE CARCINOMA OF SKIN WITH SIMULTANEOUS CYTOKERATIN EXPRESSION [J].

GREEN, WR ;

LINNOILA, RI ;

TRICHE, TJ .

ULTRASTRUCTURAL PATHOLOGY, 1984, 6 (2-3) :141-152

[77] Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction [J].

Greenfield, EM ;

Horowitz, MC ;

Lavish, SA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (18) :10984-10989

[78] Growth factor properties of VIP during early brain development -: Whole embryo culture and in vivo studies [J].

Gressens, P ;

Paindaveine, B ;

Hill, JM ;

Brenneman, DE ;

Evrard, P .

NEUROPEPTIDES IN DEVELOPMENT AND AGING, 1997, 814 :152-160

[79]

Gressens P, 1999, J PHARMACOL EXP THER, V288, P1207

[80] Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain [J].

Gressens, P ;

Marret, S ;

Hill, JM ;

Brenneman, DE ;

Gozes, I ;

Fridkin, M ;

Evrard, P .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (02) :390-397

← 3 4 5 6 7 8 9 10 11 12 →